Groman John E Reported decreased Nano Mobile Healthcare, Inc’s Stake

June 14, 2018 - By Dolores Ford

Groman John E Reported reduced Stake in Nano Mobile Healthcare, Inc

Groman John E filed with SEC a SC 13D form for Nano Mobile Healthcare, Inc. It can be found at: 000121465918004437. As reported by Groman John E, the filler decreased its stake in the stock by -1,547.79 % for 1,387,363 shares. Groman John E currently owns 37.82% of the stock. Date of activity: June 4, 2018.

Reasons Why Groman John E Holds Nano Mobile Healthcare, Inc

Item 4.Purpose of Transaction

The Reporting Person, as the beneficial owner of the securities of the Issuer, holds such securities for investment purposes. Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire, directly or indirectly, additional shares of

common stock and other securities

and/or retain and/or sell all or a portion of the shares of

common stock

and/or the Series B Preferred Stock and/or Series C Preferred Stock and/or Series D Preferred Stock after converting to common stock, held by the Reporting Person in the open market or in privately negotiated transactions. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person’s review of numerous factors, including, among other things, the price levels of the

common stock and

, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Person has no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

SEC Form 13D.

It closed at $0.0004 lastly. It is down 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Nano Mobile Healthcare, Inc. operates as a mobile health technology firm in the United States. The company has market cap of $321,463. The firm develops personalized and point-of-care screening using applications based upon chemical sensing methods. It currently has negative earnings. It has a strategic partnership with Theranostics Laboratory, a translational research company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.